S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
Juan Miguel Bergua Burgués(Hospital San Pedro de Alcántara), Pau Montesinos(Instituto de Salud Carlos III), Joaquín Gómez Espuch(Hospital Universitario Virgen de la Arrixaca), Eva Barragán(Hospital Universitari i Politècnic La Fe), David Martínez‐Cuadrón(Instituto de Salud Carlos III), Ferran Vall‐Llovera Calmet(University Hospital Mútua de Terrassa), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Ignacio Casas-Avilés(Hospital San Pedro de Alcántara), Fernando Ramos(Hospital de León), Laura Torres Miñana(Hospital Universitari i Politècnic La Fe), Antonio García-Guiñón(Hospital Arnau de Vilanova), Evelyn Acuña‐Cruz(Hospital Universitari i Politècnic La Fe), Mercedes Colorado(Marqués de Valdecilla University Hospital), Blanca Boluda(Hospital Universitari i Politècnic La Fe), Maria Victoria Verdugo(Hospital Jerez Puerta del Sur), Rosa Ayala(Hospital Universitario 12 De Octubre), Antònia Sampol, Marta Valero(Hospital Arnau de Vilanova), Isabel Cano Ferri(Hospital Universitari i Politècnic La Fe), Rebeca Rodríguez‐Veiga
Cited by 6
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
|Journal of the American College of Cardiology|2013|631